Exelixis, Inc. (EXEL), a California-based oncology biotechnology company, has quietly become one of the steadier large-cap performers in the sector. After climbing more than 25% over the trailing year, the stock trades within striking distance of its all-time high. That has naturally raised a forward-looking question among investors: can Exelixis reach $70? The figure is appealing because it is a clean psychological milestone and because it sits meaningfully above the most optimistic published analyst price target, making it a genuine test of the bull case rather than a near-term rounding.
Exelixis develops and commercializes targeted cancer medicines. Its commercial engine is cabozantinib, sold in the United States as CABOMETYX for kidney, liver, and thyroid cancers and as COMETRIQ for medullary thyroid cancer. The company also markets COTELLIC and MINNEBRO. The real growth narrative, however, centers on zanzalintinib, a next-generation oral kinase inhibitor designed to become the company's long-term successor to cabozantinib.
The company's fundamentals are notably strong for a biotech. Trailing twelve-month revenue approaches $2.4 billion, net income is in the range of $860 million, and the business carries a modest price-to-earnings (P/E) ratio in the mid-to-high teens. In its most recent quarter, Exelixis reported earnings per share (EPS) of $0.91, ahead of consensus, with revenue rising roughly 10% year over year. A clean balance sheet and substantial cash reserves have also supported shareholder-friendly activity, including a sizable share repurchase authorization.
The clearest catalyst is the U.S. Food and Drug Administration (FDA) decision on zanzalintinib in previously treated metastatic colorectal cancer, with a regulatory decision date expected in early December 2026. Management has described this as the company's top priority and has explicitly excluded any zanzalintinib contribution from its full-year guidance, meaning approval would represent pure upside to current expectations. Continued market-share gains for cabozantinib, which remains the most-prescribed tyrosine kinase inhibitor in first-line kidney cancer, provide a stable revenue base, while buybacks reduce the share count and can support earnings growth per share.
The bear case rests primarily on concentration and pipeline risk. Cabozantinib accounts for the overwhelming majority of revenue, and its intellectual property begins to face generic pressure near the end of the decade, which is a genuine long-term overhang. Meanwhile, zanzalintinib's pivotal colorectal cancer data were described by several analysts as mixed, and the regulatory outcome is not guaranteed. A delay or rejection would remove the most visible near-term catalyst. Competitive pressure in oncology and a sector rotation away from defensive healthcare names could also weigh on sentiment.
Wall Street's view is balanced rather than emphatic. Consensus ratings cluster around Hold to Buy, with average analyst price targets in the low-to-mid $50s and a range spanning roughly $41 to $66. This is important context for the $70 question: even the most bullish published analyst price target sits below $70. Reaching that level would therefore require the market to price in catalysts, such as a successful zanzalintinib approval and meaningful commercial uptake, that analysts have not yet fully embedded in their models.
From a technical analysis perspective, the $57.57 52-week high represents the nearest resistance level and the threshold the stock must clear to enter new-high territory. A sustained break above that zone would remove a key supply area and open the path toward round-number targets. The $70 level itself functions as a psychological resistance level that has never been tested, while support can be traced toward the low-$50s and the 200-day moving average area near the high $40s.
Traders monitoring whether Exelixis can build the momentum to challenge higher price levels can use tools like Tickeron's AI Daily Buy/Sell Signals. The product uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. These signals can help traders spot emerging opportunities, keep tabs on existing positions, and identify changing market trends more efficiently than manual screening alone.
The path to $70 is possible but demanding. The strongest support comes from Exelixis's profitable core franchise, strong cash position, and a defined regulatory catalyst with upside not yet reflected in guidance. The primary risks are concentration on cabozantinib, the pending patent cliff, and the uncertainty surrounding zanzalintinib. Because $70 sits above even the highest current analyst price target, investors should monitor the December regulatory decision, any commentary on zanzalintinib's commercial potential, and whether the stock can sustain a decisive break above its 52-week high. A positive regulatory outcome coupled with strong early demand for zanzalintinib would meaningfully improve the odds that the $70 price target comes into view.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with INCY. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then INCY could also see price increases.
| Ticker / NAME | Correlation To EXEL | 1D Price Change % | ||
|---|---|---|---|---|
| EXEL | 100% | -0.20% | ||
| INCY - EXEL | 47% Loosely correlated | -0.98% | ||
| MIRM - EXEL | 42% Loosely correlated | +0.27% | ||
| ACAD - EXEL | 38% Loosely correlated | +0.57% | ||
| GMAB - EXEL | 37% Loosely correlated | -2.35% | ||
| RPRX - EXEL | 36% Loosely correlated | +0.13% | ||
More | ||||